
UPDATE ON LIDOCAINE (VERSATIS[®]) MEDICATED PLASTERS



The HSE introduced a reimbursement application system for lidocaine medicated plasters (Versatis[®]) with effect from 1 September 2017. The reimbursement of lidocaine medicated plasters (Versatis[®]) through a health technology management approach helps to ensure evidence-based and cost-effective utilisation of healthcare resources and promotes best practice prescribing.

An average of 1,731 patients were accessing lidocaine medicated plasters (Versatis[®]) each month under the Community Drug Schemes in 2023. Between September 2017 and December 2023, expenditure on lidocaine medicated plasters (Versatis[®]) under the Community Drug Schemes was €23.5 million.

April 2024

HSE Medicines Management Programme.